KBC Group
INDV icon

KBC Group’s Indivior Pharmaceuticals INDV Stock Holding History

KBC Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.31M Buy
75,831
+72,523
+2,192% +$2.4M 0.01% 632
2025
Q4 		$119K Hold
3,308
– – ﹤0.01% 1177
2025
Q3 		$80K Buy
+3,308
New +$69.2K ﹤0.01% 1396

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KBC Group's INDV Position: Q1 2026 in Review

KBC Group increased its Indivior Pharmaceuticals (INDV) stake by 2,192% in Q1 2026, buying an estimated $2.4M and bringing the position to 75,831 shares worth $2.31M. The position accounts for 0.01% of the portfolio, ranked #632.

KBC Group first reported a position in INDV in Q3 2025 and has held it in 3 quarters since. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • KBC Group held 75,831 shares of Indivior Pharmaceuticals worth $2.31M as of Q1 2026.
  • KBC Group bought 72,523 Indivior Pharmaceuticals shares in Q1 2026, an estimated $2.4M.
  • Indivior Pharmaceuticals made up 0.01% of KBC Group's portfolio in Q1 2026, its #632 holding.
  • KBC Group first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.